Ophthalmic company Ocuphire Pharma (Nasdaq: OCUP), a specialist in retinal and refractive eye disorders, together with partner Viatris (Nasdaq: VTRS), have secured US approval for Ryzumvi (phentolamine).
The nod covers use of the therapy for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists or parasympatholytic agents.
The decision was made on the basis of the MIRA clinical trial program, involving more than 600 subjects, including the MIRA-1 Phase IIb trial, MIRA-2 and MIRA-3 Phase III trials.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze